Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.
The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback